Brilinta Approval Shows AstraZeneca's Success With Aspirin Theory, But Can It Change The Market?
• By Shirley Haley
FDA appears to have come around to the "aspirin hypothesis" offered by AstraZeneca PLC to explain poor results for North American patients who took the blood-thinner Brilinta, though labeling takes a somewhat cautious approach that reflects initial concerns about that explanation.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
